Conception and design: Dashti, LaRocca. Acquisition of data: Dashti, Yao. Analysis and interpretation of data: Dashti, Kadner, LaRocca. Critically revising the article: Spalding, Sun, LaRocca. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Dashti. Administrative/technical/material support: Kadner, Kumar. Study supervision: LaRocca.
Boockvar JATsiouris AJHofstetter CPKovanlikaya IFralin SKesavabhotla K: Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 114:624–6322011
Epenetos AACourtenay-Luck NPickering DHooker GDurbin HLavender JP: Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J (Clin Res Ed) 290:1463–14661985
Levin VABidaut LHou PKumar AJWefel JSBekele BN: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–14952011. (Erratum in Int J Radiat Oncol Biol Phys 84: 6 2012)
Namba HKobayashi SIwadate YSaegusa TSato AWatanabe Y: Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl-propyleneamine oxime—technical note. Neurol Med Chir (Tokyo) 34:832–8351994
Vredenburgh JJDesjardins AKirkpatrick JPReardon DAPeters KBHerndon JE II: Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 82:58–662012